Asuragen to Present at 2017 American Society of Human Genetics (ASHG) Conference

Presentations to focus on diagnostic solutions for repeat expansion disorders

AUSTIN, Texas--()--Asuragen, Inc., a molecular diagnostics products company changing the way patients are treated in genetics and oncology by bringing complex molecular tests to hospital and reference labs, will present two posters and participate in a workshop panel sponsored by Thermo Fisher Scientific at the upcoming American Society of Human Genetics (ASHG) Conference on October 17-21 in Orlando, Florida.

“Our focus at ASHG this year is on our growing product pipeline for neurodegenerative and neurodevelopmental disorders, including myotonic dystrophy and Huntington’s disease, which are characterized by repetitive DNA sequences that are difficult to analyze,” said Matthew McManus, M.D., Ph.D., President and CEO of Asuragen. “Our proprietary chemistries empower clinical researchers to interrogate these challenging sequences with an efficient workflow and reliable performance.”

The Thermo Fisher Scientific Exhibitor Education Event will take place on Thursday, October 19 from 12:30 p.m. – 1:45 p.m. and will feature a presentation by Gary J. Latham, Ph.D., Senior Vice President of Research and Development at Asuragen, called, “Repeating themes in inherited disease and reproductive health: Resolving DNA repeat expansions using AmplideX® PCR Chemistry with the SeqStudio Genetic Analyzer.”

The posters being presented at the conference are:

Poster Session: Thursday, October 19 from 3:00 – 4:00 p.m.
Development of a unified DMPK and CNBP PCR workflow for determining repeat expansions relevant to myotonic dystrophies (Jacob Wisotsky, M.S.)

Poster Session: Friday, October 20 from 11:30 a.m. – 12:30 p.m.
Clinical correlations of a streamlined molecular assay based on AmplideX® PCR/CE technology that determines repeat size for both normal and expanded alleles in DMPK for myotonic dystrophy (Bradley Hall, Ph.D.)

About Asuragen

Asuragen is a molecular diagnostic company changing the way patients are treated in genetics and oncology. The quality, simplicity and sensitivity of its products brings precision medicine within reach. Asuragen’s diagnostic systems, composed of proprietary chemistry and software, deliver powerful answers using broadly installed instrument platforms. They are simple to adopt and expand the ability to serve patients. Asuragen is a product foundry rapidly and efficiently addressing current and emerging clinical needs, including cancer diagnosis and monitoring, reproductive health and aging, serving laboratories across a patient’s lifespan with its best in class diagnostic tests. For more information, visit www.asuragen.com.

Contacts

Asuragen, Inc.
Lynne Hohlfeld, 512-681-5200
SVP, Corporate Development and CFO
lhohlfeld@asuragen.com
or
Pure Communications, Inc.
Media:
Stephanie Collins, 512-693-4873
stcollins@purecommunicationsinc.com
or
Investors:
Courtney Dugan, 212-257-6723
cdugan@purecommunications.com

Contacts

Asuragen, Inc.
Lynne Hohlfeld, 512-681-5200
SVP, Corporate Development and CFO
lhohlfeld@asuragen.com
or
Pure Communications, Inc.
Media:
Stephanie Collins, 512-693-4873
stcollins@purecommunicationsinc.com
or
Investors:
Courtney Dugan, 212-257-6723
cdugan@purecommunications.com